J Korean Med Sci.  2024 Feb;39(7):e97. 10.3346/jkms.2024.39.e97.

Short Combination Treatment for Latent Tuberculosis in Children

• Cho HK

• KMID: 2553322
• DOI: http://doi.org/10.3346/jkms.2024.39.e97

Reference

1. Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015; 169(3):247–255. PMID: 25580725.

2. Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016; 16(11):1269–1278. PMID: 27522233.

3. Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023; 22(5):387–409. PMID: 36973491.

4. Kim Y, Bae KS, Choi UY, Han SB, Kim JH. Current status of latent tuberculosis infection treatment among pediatric patients in Korea: prescription and treatment completion. J Korean Med Sci. 2024; 39(7):e64.

5. Centers for Disease Control and Prevention. TB Treatment for Children. Updated 2016. Accessed February 13, 2024. https://www.cdc.gov/tb/topic/treatment/children.htm .

6. Batt J, Khan K. Responsible use of rifampin for the treatment of latent tuberculosis infection. CMAJ. 2019; 191(25):E678–E679. PMID: 31235488.

7. Yu S, Sohn H, Kim HY, Kim H, Oh KH, Kim HJ, et al. Evaluating the impact of the nationwide public-private mix (PPM) program for tuberculosis under National Health Insurance in South Korea: A difference in differences analysis. PLoS Med. 2021; 18(7):e1003717. PMID: 34260579.